Table A.7.
Proportion of non-completion of study follow-up by site and by regimen
| 3HP-DOT* | 9H-SAT* | |||
|---|---|---|---|---|
| Non-completion of follow-up | Enrollments (n = 3644) | Non-completion of follow-up | Enrollments (n = 3418) | |
| Enrolling site | n (% of enrollments) | n (%) | n (% of enrollments) | n (%) |
| G | 73 (12.5) | 584 (16.0) | 72 (12.7) | 569 (16.6) |
| R | 36 (13.6) | 265 (7.3) | 33 (13.2) | 250 (7.3) |
| B | 34 (20.6) | 165 (4.5) | 35 (21.1) | 166 (4.9) |
| Y | 26 (10.4) | 250 (6.9) | 24 (9.5) | 252 (7.4) |
| P | 19 (7.8) | 245 (6.7) | 25 (10.0) | 250 (7.3) |
| D | 17 (33.3) | 51 (1.4) | 20 (31.3) | 64 (1.9) |
| O | 16 (18.2) | 88 (2.4) | 19 (17.4) | 109 (3.2) |
| M | 14 (10.1) | 138 (3.8) | 12 (14.6) | 82 (2.4) |
| U | 14 (31.1) | 45 (1.2) | 15 (30.0) | 50 (1.5) |
| E | 13 (7.4) | 176 (4.8) | 5 (4.5) | 112 (3.3) |
| AA | 13(7.5) | 174 (4.8) | 24 (13.0) | 185 (5.4) |
| J | 12 (13.2) | 91 (2.5) | 5(6.1) | 82 (2.4) |
| F | 11 (6.6) | 166 (4.6) | 14 (10.9) | 128 (3.7) |
| N | 11 (16.7) | 66 (1.8) | 7(13.2) | 53(1.6) |
| Q | 11 (7.6) | 144 (4.0) | 15 (14.4) | 104 (3.0) |
| W | 11 (22.4) | 49 (1.3) | 14 (22.2) | 63 (1.8) |
| K | 10 (6.0) | 168 (4.6) | 38 (25.2) | 151 (4.4) |
| V | 9 (9.4) | 96 (2.6) | 14 (18.9) | 74 (2.2) |
| C | 8 (8.1) | 99 (2.7) | 9 (8.3) | 109 (3.2) |
| L | 8(5.6) | 142 (3.9) | 10 (7.5) | 134 (3.9) |
| I | 7 (4.5) | 155 (4.3) | 7 (4.6) | 151 (4.4) |
| Z | 7 (9.6) | 73 (2.0) | 6(7.1) | 84 (2.5) |
| A | 6 (30.0) | 20 (0.5) | 6 (46.2) | 13 (0.4) |
| X | 3 (10.7) | 28 (0.8) | 8 (27.6) | 29 (0.8) |
| T | 2 (2.2) | 93 (2.6) | 8 (8.4) | 95 (2.8) |
| H | 1 (2.1) | 48 (1.3) | 2 (5.4) | 37 (1.1) |
| S | 1 (4.3) | 23 (0.6) | 1 (4.5) | 22 (0.6) |
| KK | 0 | 1 (0.0) | 0 | 0 |
*
3HP-DOT = 3 months of directly observed once-weekly RPT (maximum dose, 900 mg) plus INH (maximum dose, 900 mg); 9H-SAT = 9 months of daily self-administered INH (maximum dose, 300 mg).
H, INH = isoniazid; P, RPT = rifapentine; DOT = directly observed therapy; SAT = self-administered treatment.